Anti-TROP2 Antibody
Based on 1 Customer Validation
Anti-TROP2 Antibody (RN927C antibody) is a human monoclonal antibody targeting Trop-2. Anti-TROP2 Antibody exerts in vitro inhibitory effects on a variety of tumor cell lines. Anti-TROP2 Antibody exhibits anti-tumor activity in mouse pancreatic PDX, ovarian PDX, lung PDX and triple-negative breast cancer (TNB) PDX models. Anti-TROP2 Antibody can be used for research on pancreatic cancer, ovarian cancer, lung cancer and triple-negative breast cancer.
For research use only. We do not sell to patients.
- Purity: 96.44%
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG1 kappa
Human
Anti-TROP2 Antibody (0.1-10 μg/mL; overnight) induces mitotic arrest in Trop-2-positive BxPC3 pancreatic cancer cells[1].
Anti-TROP2 Antibody (0.004-267 nM; 4 days) potently kills a variety of Trop-2-expressing human tumor cell lines, with an IC50 value reaching the sub-nanomolar range[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BxPC3 pancreatic cancer cells, SW620 colon cancer cells
-
Concentration:0.1, 1, 10 μg/mL
-
Incubation Time:overnight
-
Result:Induced a dramatic increase in phosphorylated histone H3-positive cells in Trop-2-positive BxPC3 cells at 0.1 μg/mL, indicating widespread mitotic arrest.
Caused BxPC3 cells to detach from slides due to cell death at 10 μg/mL.
Showed no increase in phosphorylated histone H3 staining in Trop-2-negative SW620 cells at 10 μg/mL compared to untreated cells.
-
Cell Line:A431, Fadu, OVCAR3, BxPC3, Calu-3, NCI-H292, NCI-H1650, HCC-827, MDA-MB-468, Colo205, SKBR3, SW620
-
Concentration:0.004-267 nM
-
Incubation Time:4 days
-
Result:Potently killed most Trop-2-expressing cell lines (A431, Fadu, OVCAR3, BxPC3, Calu-3, NCI-H292, NCI-H1650, HCC-827, MDA-MB-468, Colo205, SKBR3 cells), with IC50 values of 0.202, 0.507, 0.56, 0.674, 0.533, 0.633, 1.92, 0.779, 0.773, 5.06, 0.42 nM.
Showed no cytotoxicity toward Trop-2-negative SW620 cells, despite free PF-06380101 payload being active against SW620 cells with an IC50 of 0.305 nM.
Anti-TROP2 Antibody (0.75-3.0 mg/kg; i.v.; single bolus administration/once every 2 weeks; 2 doses total) induces regression of mouse Pan0123 pancreatic PDX xenograft tumors[1].
Anti-TROP2 Antibody (0.75-3.0 mg/kg; i.v.; single bolus) induces regression and eradication of Ova196756 ovarian PDX xenograft tumors in mice[1].
Anti-TROP2 Antibody (1.5 mg/kg; i.v.; single bolus administration) induces sustained regression of TROP2 LG0476 lung cancer PDX xenografts in mice[1].
Anti-TROP2 Antibody (1.5 mg/kg; i.v.; single bolus; repeated administration 63 days after the first dose) induces long-term regression of large CTG-1017 triple-negative breast cancer PDX xenografts in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CB17/SCID (female, 5-6 weeks old, pancreatic cancer xenograft with 2 million BxPC3 cells implanted subcutaneously)[1]
-
Dosage:0.75 mg/kg; 1.5 mg/kg; 3.0 mg/kg
-
Administration:i.v.; single bolus injection
-
Result:Induced tumor regression at 1.5 mg/kg and 3.0 mg/kg doses.
Inhibited tumor growth at 0.75 mg/kg dose compared to controls.
-
Animal Model:CB17/SCID (female, pancreatic cancer PDX xenograft with 1-2 mm3 Pan0123 fragments implanted subcutaneously)[1]
-
Dosage:0.75 mg/kg; 1.5 mg/kg; 3.0 mg/kg
-
Administration:i.v.; single bolus injection/i.v.; every 2 weeks; 2 total doses
-
Result:Induced tumor regression at all tested single doses, with the most persistent regression seen at higher doses.
-
Animal Model:CB17/SCID (female, ovarian cancer PDX xenograft with 1-2 mm3 Ova196756 fragments implanted subcutaneously)[1]
-
Dosage:0.75 mg/kg; 1.5 mg/kg; 3.0 mg/kg
-
Administration:i.v.; single bolus injection
-
Result:Induced tumor regression at all tested single doses.
Induced more persistent regression and tumor eradication at doses ≥1.5 mg/kg.
-
Animal Model:CB17/SCID (female, lung cancer PDX xenograft with 1-2 mm3 LG0476 fragments implanted subcutaneously)[1]
-
Dosage:1.5 mg/kg
-
Administration:i.v.; single bolus injection
-
Result:Induced sustained tumor regression.
Showed superior efficacy over gemcitabine treatment (tumor regrew sooner) and paclitaxel treatment (only partial growth inhibition).
-
Animal Model:CB17/SCID (female, triple-negative breast cancer PDX xenograft with 1-2 mm3 CTG-1017 fragments implanted subcutaneously)[1]
-
Dosage:1.5 mg/kg
-
Administration:i.v.; single bolus injection; repeated 63 days after first dose
-
Result:Induced tumor regression lasting more than 60 days with the first single dose.
Induced another long-duration tumor regression after retreatment of regrown tumors.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Anti-TROP2 Antibody]
-
Synonyms
RN927C antibody
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (265 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-TROP2 Antibody Related Classifications
HY-P991372 Related Classifications
Powered by Bioz